Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alexander Otsetov"'
Autor:
Natasha Takova, Alexander Otsetov
Publikováno v:
Modern Research in Inflammation. :29-36
Paraneoplastic syndromes (PS) represent a large spectrum of symptoms, associated with malignant diseases. PS can be diagnosed in asymptomatic patients with occult carcinoma, clinically active cancer, and during clinical remission, suggesting a recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f3c456954886490a9816f377824e247
https://doi.org/10.4236/mri.2017.64004
https://doi.org/10.4236/mri.2017.64004
Autor:
Alexander Otsetov
Publikováno v:
Current Bladder Dysfunction Reports. 11:140-145
The most common non-malignant, age-related disease in men is the benign prostatic hyperplasia (BPH). Androgens and genetic predisposition play important roles in normal prostate growth and in BPH p ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5619b64dc505d5cb65fc15faa409a524
https://doi.org/10.1007/s11884-016-0361-8
https://doi.org/10.1007/s11884-016-0361-8
Publikováno v:
International Clinical Pathology Journal. 6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b11c8b6fe39191d9c3c82deeaaaf34c
https://doi.org/10.15406/icpjl.2018.06.00161
https://doi.org/10.15406/icpjl.2018.06.00161
Autor:
Mark Vangel, Alexander Otsetov, Seth Bechis, Zongwei Wang, Shahin Tabatabaei, Aria F. Olumi, Rongbin Ge, Chin-Lee Wu
Publikováno v:
Journal of Urology. 194:1031-1037
In men with symptomatic benign prostatic hyperplasia 5α-reductase inhibitors are a main modality of treatment. More than 30% of men do not respond to the therapeutic effects of 5α-reductase inhibitors. We have found that a third of adult prostate s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffcb43abdd6a495e04faf49016f60f93
https://doi.org/10.1016/j.juro.2015.04.079
https://doi.org/10.1016/j.juro.2015.04.079
Autor:
Chin-Lee Wu, Shulin Wu, Seth Bechis, Shengyu Hua, Aria F. Olumi, Alexander Otsetov, Shahin Tabatabaei, Zongwei Wang, Rongbin Ge
Publikováno v:
The American Journal of Pathology. 185:870-882
5-α Reductase type 2 (SRD5A2) is a critical enzyme for prostatic development and growth. Inhibition of SRD5A2 by finasteride is used commonly for the management of urinary obstruction caused by benign prostatic hyperplasia. Contrary to common belief
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3854b6b5946a3a8b1264dfe1e37f1a2
https://doi.org/10.1016/j.ajpath.2014.11.020
https://doi.org/10.1016/j.ajpath.2014.11.020
Autor:
Zongwei Wang, Seth Bechis, Shengyu Hua, Shulin Wu, Alexander Otsetov, Aria F. Olumi, Shahin Tabatabaei, Ge Rongbin, Chin-Lee Wu
Publikováno v:
Cancer Research. 75:1052-1052
BACKGROUND: 5-alpha reductase type 2 (SRD5A2), an enzyme that is critical for prostatic development and growth, is utilized as an inhibitory target by finasteride for patients with bladder outlet obstrution secondary to BPH. However, we have found th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf764f39105e10dc74980d7b5e49ed12
https://doi.org/10.1158/1538-7445.am2015-1052
https://doi.org/10.1158/1538-7445.am2015-1052